We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Approval is based on positive data from the Phase 3 ECHELON-3 trial
TFOS is indicated for the treatment of pulmonary arterial hypertension
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Plans underway to expand screening capacity by 50% for greater accessibility
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Subscribe To Our Newsletter & Stay Updated
